ConductScience.org, home

Paper35100718

Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma.

Roderwieser A and 20 others. JCO Precis Oncol, 2019. Cited by 53 papers, by iCite.

Cite this record

ConductScience Library. Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma. Papers, record 35100718. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35100718

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma.
PubMed
Journal
JCO Precis Oncol
PubMed
Year
2019
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
53
iCite
Relative citation ratio, by iCite
1.89
iCite
Revised in PubMed
2022-02-01
PubMed

Authors21

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Roderwieser AAndrea
2Sand FFrederik
3Walter EEsther
4Fischer JJanina
5Gecht JJudith
6Bartenhagen CChristoph
7Ackermann SSandra
8Otte FFelix
9Welte AAnne
10Kahlert YYvonne
11Lieberz DDaniela
12Hertwig FFalk
13Reinhardt HCH Christian
14Simon TThorsten
15Peifer MMartin
16Ortmann MMonika
17Büttner RReinhard
18Hero BBarbara
19O'Sullivan RJRoderick J
20Berthold FFrank

Source PubMed

See all 21 authorsDownload CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06502210Identification of New Gene Spliceosomes in NeuroblastomaBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by44

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 53 citations.

PMIDTitleJournalYearIn PapersSource
42957633SFRP2+ fibroblasts orchestrate post-chemotherapy remodeling and define a tumor-driven prognostic program, NBTRP, in adrenal neuroblastoma.Cell Death Dis2026https://conductscience.org/library/papers/42957633PubMed
42677450Integrated Genomic and Proteomic Analysis Reveals T-B Lymphocyte Signatures in the MYCN Driven "Immune Desert" of Specific Neuroblastoma Subtypes.CNS Neurosci Ther2026https://conductscience.org/library/papers/42677450PubMed
42385103Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.JCO Precis Oncol2026https://conductscience.org/library/papers/42385103PubMed
42279325Targeted Therapies in Neuroblastoma: A History and a View to the Future.Cancers (Basel)2026https://conductscience.org/library/papers/42279325PubMed
41948996Telomere damage enhances immunogenicity of neuroblastoma and accelerates response to anti-PD-L1 treatment.Oncoimmunology2026https://conductscience.org/library/papers/41948996PubMed
41858373Telomere maintenance mechanisms are activated in ganglioneuroblastoma and ganglioneuroma.Oncol Lett2026https://conductscience.org/library/papers/41858373PubMed
41714805What does BCL-2 do? From new molecular insights to the clinical implications.Cell Death Differ2026https://conductscience.org/library/papers/41714805PubMed
41595154Molecular Features Associated with a High-Risk Clinical Course in Neuroblastomas Initially Diagnosed as Non-High-Risk.Cancers (Basel)2026https://conductscience.org/library/papers/41595154PubMed
40591170Integrated single-cell and bulk RNA sequencing analysis establishes a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in neuroblastoma.Discov Oncol2025https://conductscience.org/library/papers/40591170PubMed
40158050Peripheral neuroblastic tumors behaving badly: an update on high-risk morphologic and molecular groupings.Virchows Arch2025https://conductscience.org/library/papers/40158050PubMed
40115016Mechanisms and molecular characterization of relapsed/refractory neuroblastomas.Front Oncol2025https://conductscience.org/library/papers/40115016PubMed
39796644Prognostic Value of Molecular Aberrations in Low- or Intermediate-Risk Neuroblastomas: A Systematic Review.Cancers (Basel)2024https://conductscience.org/library/papers/39796644PubMed
39780220The Venus score for the assessment of the quality and trustworthiness of biomedical datasets.BioData Min2025https://conductscience.org/library/papers/39780220PubMed
39348606TERT Expression and Clinical Outcome in Pulmonary Carcinoids.J Clin Oncol2025https://conductscience.org/library/papers/39348606PubMed
39133652Preclinical spheroid models identify BMX as a therapeutic target for metastatic MYCN nonamplified neuroblastoma.JCI Insight2024https://conductscience.org/library/papers/39133652PubMed
38962012A mitochondria-related genes associated neuroblastoma signature - based on bulk and single-cell transcriptome sequencing data analysis, and experimental validation.Front Immunol2024https://conductscience.org/library/papers/38962012PubMed
38891878Long Non-Coding RNAs in Neuroblastoma: Pathogenesis, Biomarkers and Therapeutic Targets.Int J Mol Sci2024https://conductscience.org/library/papers/38891878PubMed
38763334Pan-cancer analysis of telomere maintenance mechanisms.J Biol Chem2024https://conductscience.org/library/papers/38763334PubMed
382953205-Hydroxymethylcytosine Profiling of Cell-Free DNA Identifies Bivalent Genes That Are Prognostic of Survival in High-Risk Neuroblastoma.JCO Precis Oncol2024https://conductscience.org/library/papers/38295320PubMed
38180812METTL3 drives telomere targeting of TERRA lncRNA through m6A-dependent R-loop formation: a therapeutic target for ALT-positive neuroblastoma.Nucleic Acids Res2024https://conductscience.org/library/papers/38180812PubMed

See all 44 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35100718

GET https://conductscience.org/api/papers/v1/35100718/authors?page=2